基于MRI的影像组学特征作为低级别胶质瘤总生存期和化疗获益的治前无创预测指标
研究从149例低级别胶质瘤患者的术前轴位FLAIR和增强T1加权序列提取影像组学特征,用Lasso Cox回归构建影像组学特征,并在66例独立验证组中验证。联合CE-T1-w和FLAIR的影像组学特征预测总生存的C指数为0.798,优于单序列;联合临床病理列线图的影像组学列线图C指数0.821,优于单纯临床病理列线图的0.692(p<0.001)。影像组学特征为独立预后因素,且高影像组学特征患者似乎更易从化疗中获益。
要点
- 联合增强T1加权与FLAIR序列的影像组学特征预测低级别胶质瘤总生存的C指数为0.798。
- 影像组学特征为独立预后因素,联合临床病理列线图后预测总生存的C指数达0.821。
- 高影像组学特征患者似乎更易从化疗中获益。
核心结论
- 影像组学特征独立于临床病理数据,是无创的治前预测低级别胶质瘤患者生存的指标,并可预测哪些患者从化疗中获益。
研究设计与样本
- 研究论文;影像组学特征构建队列149例低级别胶质瘤患者,独立验证队列66例;从轴位平扫FLAIR和增强轴位T1加权序列提取特征;采用Lasso Cox回归模型筛选特征并构建影像组学特征;以总生存为终点,建立联合影像组学特征与临床病理列线图的影像组学列线图。
诊断标准与关键数值
- 联合CE-T1-w和FLAIR影像组学特征预测总生存的C指数为0.798,优于CE-T1-w单序列的0.744和FLAIR单序列的0.736。
- 联合影像组学特征与临床病理列线图的影像组学列线图预测总生存的C指数为0.821,优于单纯临床病理列线图的0.692(p<0.001)。
临床应用与阅片要点
- 影像组学特征可作为治前无创工具,辅助预测低级别胶质瘤患者的总生存。
- 高影像组学特征的患者似乎更易从化疗中获益,可能有助于筛选化疗获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to develop and validate a radiomics signature for predicting survival and chemotherapeutic benefits of patients with lower-grade gliomas (LGG).
METHODS: Radiomics features were extracted from precontrast axial fluid-attenuated inversion recovery (FLAIR) and contrast-enhanced axial T-1 weighted (CE-T1-w) sequence. Lasso Cox regression model was used for feature selection and radiomics signature building. The radiomics signature was developed in a primary cohort that consisted of 149 LGG patients and was then validated on an entirely new validation cohort that contained 66 LGG patients. A radiomics nomogram for the prediction of OS was established by adding the radiomics to clinicopathologic nomogram which developed with clinical data.
RESULTS: A radiomics signature derived from joint CE-T1-w and FLAIR images showed better prognostic performance (C-index, 0.798) than signatures derived from CE-T1-w (C-index, 0.744) or FLAIR (C-index, 0.736) sequences alone. Multivariable Cox regression revealed that the radiomics signature was an independent prognostic factor. One radiomics nomogram integrated the radiomics signature from joint CE-T1-w and FLAIR sequences with the clinicopathologic nomogram outperformed the clinicopathologic nomogram based on clinicopathologic data alone in predicting OS of LGG (C-index, 0.821 vs. 0.692; p < 0.001). Further analysis revealed that patients with higher radiomics signature were prone to benefit from chemotherapy.
CONCLUSIONS: The radiomics signature was independent with clinicopathologic data and was a noninvasive pretreatment predictor for LGG patients' survival. Moreover, it could predict which patients with LGG benefit from chemotherapy.
KEY POINTS: • A radiomics signature derived from joint CE-T1-w and FLAIR sequences showed better prognostic performance than signatures derived from either single imaging modality. • The radiomics signature is an independent prognostic factor and outperformed clinicopathologic features in predicting overall survival of LGG patients. • The radiomics signature could help preoperatively identify LGG patients who may benefit from chemotherapy.
引用
- Wang J, Zheng X, Zhang J, et al. An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas. Eur Radiol. 2021. PMID: 33409797. doi:10.1007/s00330-020-07581-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。